Raffaella Casolino, Technical Officer in the Department of Noncommunicable Diseases, Rehabilitation, and Disability at WHO in Geneva, shared on LinkedIn:
“One week on from the launch of The Lancet Oncology Commission on Cancer Genomics and Precision Oncology. I remain humbled by the scale of the collaboration and the ambition of its vision.
–
Title: Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission
Authors: Raffaella Casolino, Joaquin Mateo, Elisabeth G. E. de Vries, Amber Johns, Melanie Courtot, Rita T. Lawlor, Sandra Perdomo, Stacy W. Gray, Raquel Perez-Lopez, Clare Turnbull, David Torrents, Kerstin Noelle Vokinger, Dilara Akhoundova, Jean-Marc Bourque, Andrés F. Cardona, Yoon Jung Chang, Debyani Chakravarty, Ievgeniia Chicherova, Karen Ann Cranston, Melissa Davis, Amanda Drury, Oskar Frisell, Raquel Manzano Garcia, Robert L. Grossman, Yosr Hamdi, Simon Hediger, Thomas Hofmarcher, Oliver Hofmann, Jakob Nikolas Kather, Hannah Kim, Kazuto Kato, Bartha Maria Knoppers, Kjong-Van Lehmann, Dilani Lokuhetty, Patricia M. LoRusso, Deborah Mascalzoni, Nicola Mulder, Travis Osterman, Folakemi Odedina, Aparna R. Parikh, Solomon Rotimi, Brian Rous, Shawn Sweeney, Bhawna Sirohi, Zbyslaw Sondka, Ciara Staunton, Kjetil Taskén, Alex Wagner, C Benedikt Westphalen, Jianmin Wu, Joly Yann, Ma’n H Zawati, Andrew V Biankin, Takayuki Yoshino, Lincoln Stein, Mark Lawler
–
Realising the potential of precision oncology requires an entire ecosystem: evidence, policy, diagnostics, medicines, data infrastructure, a genomics-capable workforce, and health systems able to translate genomic information into meaningful patient benefit.
The collection of work published alongside the Commission helps bring these challenges into sharper focus. Beyond the Commission report itself, this body of work comprises six regional reviews, six technical papers, and a series of Precision Oncology Snapshots.
Together, these publications offer one the most extensive assessments to date of the opportunities, barriers, and solutions shaping the adoption of cancer genomics and precision oncology across diverse health systems worldwide:
- Cancer susceptibility.
- Global uptake of essential cancer medicines requiring complex genomic diagnostics.
- Competency-based framework for precision oncology.
- Role of nurses in precision oncology.
- Cancer genomic data ecosystems.
Meaningful patient engagement throughout research, implementation and care.
–
Title: Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia
Authors: Hideaki Bando, Hirokazu Okayama, Yoon Jung Chang, Jinpu Yu, Sean M. Grimmond, Sun-Young Kong, Xin Hu, Nikolajs Zeps, Ji-Youn Han, Jong-Il Kim, Kyosuke Seguchi, Masataka Amisaki, Yasutoshi Sakamoto, Takao Fujisawa, Riu Yamashita, Kazuto Kato, Koji Kono, Amber Johns, Takayuki Yoshino
–
Title: Landscape of cancer genomics and precision oncology in Europe
Authors: Gro Live Fagereng, Edvard Abel, Raffaella Casolino, Ruggero De Maria, Stefan Fröhling, Hans Gelderblom, Alberto Hernando-Calvo, Sue Hill, Katriina Jalkanen, Maud Kamal, Matthew G. Krebs, Mark Lawler, Christophe Le Tourneau, Anni Lepland, Iwona Ługowska, Beatrice Mainoli, Nicola Normanno, Radka Lordick Obermannova, Alejandro Piris-Giménez, Kristoffer Stahl Rohrberg, Bettina Ryll, Marc van den Bulcke, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Els Van Valckenborgh, Loic Verlingue, C. Benedikt Westphalen, Kjetil Taskén
–
I hope our frameworks and practical recommendations will be useful to Member States and implementing partners as they translate precision oncology into practice and I look forward to the actions that follow.
On a personal note, I’d like to share a message with younger colleagues: believe in your ideas. This one began during my PhD and, years later, grew into a Lancet Oncology Commission. If you believe your idea matters, follow it. You will find many obstacles along the way, but also people who see its potential, support you, and open doors you may not have imagined.
I will always be grateful to David Collingridge, EiC of The Lancet Oncology, for believing in this one and giving it the chance to become something far bigger than I could imagined.
A huge thanks to everyone who contributed across disciplines, institutions, countries and regions!”
You can also read:
Precision Oncology After Chemoimmunotherapy in Biliary Tract Cancer
